In addition, our current study cannot exclude the possibility that intrathecal injection of an inhibitor may also block NFAT1 pathway activity in dorsal root ganglion neurons, thereby partially contributing to the alleviation of bone cancer pain. Here, NFATC2 is linked to bone cancer.